Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betahistin (ausschl. Wirkstärke 6 mg und 12 mg) f. d. Z. 01.10.2026 - 30.09.2028 (zzgl. V.-Option 1x12 Mon)

Section 130a, paragraph 8, SGB V allows health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For the medicines to be specified by the bidder in more detail in Annex 2 to the contract for the aforementioned active substance Betahistin (exclusively strengths 6 mg and 12 mg), ATC N07CA01, DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until new medicine discount contracts come into force. A discount contract under the authorisation model for the aforementioned active substance will come into force for the first time on 01.10.2026 and will end on 30.09.2028 (plus extension option 1x12 months). It will automatically end, regardless, with the coming into force of the exclusive contract.